NASDAQ:NEUP Neuphoria Therapeutics Inc. - Common Stock 2/14/2025 Earnings Report $6.70 -0.12 (-1.76%) As of 03:59 PM Eastern ProfileEarnings HistoryForecast Neuphoria Therapeutics Inc. - Common Stock EPS ResultsActual EPS-$1.23Consensus EPS -$2.01Beat/MissBeat by +$0.78One Year Ago EPSN/ANeuphoria Therapeutics Inc. - Common Stock Revenue ResultsActual Revenue$660.00 billionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ANeuphoria Therapeutics Inc. - Common Stock Announcement DetailsQuarterDate2/14/2025TimeBefore Market OpensConference Call DateN/AConference Call TimeN/AConference Call ResourcesEarnings HistoryCompany Profile Neuphoria Therapeutics Inc. - Common Stock Earnings HeadlinesNeuphoria to Present at the American Society of Clinical Psychopharmacology (ASCP) 2025 Annual MeetingMay 27, 2025 | globenewswire.comNeuphoria Therapeutics, Inc.: Neuphoria Provides First Quarter 2025 Business UpdatesMay 21, 2025 | finanznachrichten.deWill I be blacklisted?The President’s tour of the Middle East… the deal for Ukraine’s mineral rights… Elon’s strange time in Washington… even Trump’s obsession with seizing Greenland. There’s a singular force that connects the dots… And it could threaten to transform American life – and your wealth – forever. June 16, 2025 | Porter & Company (Ad)Neuphoria Provides First Quarter 2025 Business UpdatesMay 20, 2025 | globenewswire.comNeumora Therapeutics, Inc. Common Stock (NASDAQ:NMRA) Q1 2025 Earnings Call TranscriptMay 14, 2025 | msn.comNeuphoria Therapeutics provides review of 2024, highlights 2025 plansApril 16, 2025 | markets.businessinsider.comSee More Neuphoria Therapeutics Inc. - Common Stock Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Neuphoria Therapeutics Inc. - Common Stock? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Neuphoria Therapeutics Inc. - Common Stock and other key companies, straight to your email. Email Address About Neuphoria Therapeutics Inc. - Common StockNeuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.View Neuphoria Therapeutics Inc. - Common Stock ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Broadcom Slides on Solid Earnings, AI Outlook Still StrongFive Below Pops on Strong Earnings, But Rally May StallRed Robin's Comeback: Q1 Earnings Spark Investor HopesOllie’s Q1 Earnings: The Good, the Bad, and What’s NextBroadcom Earnings Preview: AVGO Stock Near Record HighsUlta’s Beautiful Q1 Earnings Report Points to More Gains Aheade.l.f. Beauty Sees Record Surge After Earnings, Rhode Deal Upcoming Earnings Accenture (6/20/2025)FedEx (6/24/2025)Micron Technology (6/25/2025)Paychex (6/25/2025)NIKE (6/26/2025)Bank of America (7/14/2025)Wells Fargo & Company (7/14/2025)JPMorgan Chase & Co. (7/14/2025)Interactive Brokers Group (7/15/2025)América Móvil (7/15/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
